CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 85 enrolled
Drug / intervention
Sorafenib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00390611
NCT00390611Phase 2Completed
CompareCT.gov

A Randomized Phase II Study of Paclitaxel/Carboplatin With or Without Sorafenib in the First-Line Treatment of Patients With Stage III/IV Epithelial Ovarian Cancer

SCRI Development Innovations, LLC·interventional·Posted Oct 20, 2006·Updated Dec 22, 2014

In Brief

A Phase 2 clinical trial evaluating Sorafenib, Paclitaxel, and 1 other intervention for Ovarian Cancer. Completed, enrolled 85 participants across 17 sites.

Detailed Summary

This trial will compare the efficacy and toxicity of standard first-line chemotherapy alone vs. standard chemotherapy plus sorafenib in patients with stage III/IV ovarian cancer following cytoreductive surgery. Patients with residual large volume disease and/or bowel involvement will be excluded, to minimize the risk of bowel perforation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer
CountriesUnited States
CollaboratorsBayer

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 20, 2006
Enrollment StartOct 1, 2006
Primary CompletionJul 1, 2012
Study CompletionApr 1, 2014
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 19.7 years ago

Interventions

Sorafenibdrug

Paclitaxeldrug

Paclitaxel

Carboplatindrug

Carboplatin